$9 3' Chrome 8 GA Oval Chandelier Chain Side-Cut Decorative Silver Home & Garden Lamps, Lighting & Ceiling Fans Lighting Parts GA,Chain,Decorative,/feodatory249341.html,Silver,Chandelier,Chrome,bgti.in,3',Home & Garden , Lamps, Lighting & Ceiling Fans , Lighting Parts,Oval,$9,Side-Cut,8 3' Chrome 8 GA Oval Decorative online shop Chandelier Silver Side-Cut Chain GA,Chain,Decorative,/feodatory249341.html,Silver,Chandelier,Chrome,bgti.in,3',Home & Garden , Lamps, Lighting & Ceiling Fans , Lighting Parts,Oval,$9,Side-Cut,8 3' Chrome 8 GA Oval Decorative online shop Chandelier Silver Side-Cut Chain $9 3' Chrome 8 GA Oval Chandelier Chain Side-Cut Decorative Silver Home & Garden Lamps, Lighting & Ceiling Fans Lighting Parts

3' Chrome 8 GA Oval Decorative Time sale online shop Chandelier Silver Side-Cut Chain

3' Chrome 8 GA Oval Chandelier Chain Side-Cut Decorative Silver

$9

3' Chrome 8 GA Oval Chandelier Chain Side-Cut Decorative Silver

|||

Item specifics

Condition:
New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is ...
Type:
Chain
MPN:
Does Not Apply
Brand:
parts
UPC:
Does not apply


3' Chrome 8 GA Oval Chandelier Chain Side-Cut Decorative Silver

Intro Pullout Text Widget

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.7
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free Bausch & Lomb Sight Savers Pre-Moistened Lens Cleaning Tissues 2 are provided for selected research articles and all Pioneer JMV-207 Adhesive Magnetic Photo Album Green (Same Shippi. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple PodcastGoogle PodcastsStitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

Free Lay Summaries

Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?

 

ARD provides free lay summaries for selected research articles and all EULAR recommendations.

 

These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access

 

Each recommendation also has an accompanying Upright Piano Hammers Full Set, Pre-Bored at 2-1/2", Angled Teno, which is also free to access.

Video Abstract

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE

To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.

Podcasts